SECTION 1 — MARKET OVERVIEW
Why Is the Liquid Nitrogen Market Expanding?
The global Liquid Nitrogen Market was valued at USD 17.03 billion in 2025 and is projected to reach USD 26.1 billion by 2035, registering a CAGR of 4.36% during the forecast period 2026–2035. This expansion is driven by three converging structural forces identified by Market Research Future: semiconductor fabrication expansion where global fab investment exceeding USD 380 billion through 2030 requires liquid nitrogen at every advanced-node wafer fabrication facility for cryogenic cooling, process gas inerting, and photoresist stripping; biologics cold-chain mandates where WHO GAVI Alliance requirements for temperature-controlled vaccine distribution and FDA biologics manufacturing regulations are mandating cryogenic nitrogen for vaccine storage tanks and biological sample biobanking; and the Kigali Amendment HFC phase-down that is driving refrigeration industry transitions from hydrofluorocarbon refrigerants toward nitrogen-based cryogenic cooling alternatives in large commercial food preservation applications. Liquid nitrogen — produced at -196°C through atmospheric air cryogenic distillation — serves simultaneously as a cryogenic industrial coolant, inert blanket gas, food blast-freezing medium, biological sample preservation agent, and semiconductor process gas across diverse industries.
The Liquid Nitrogen Market is structured around three primary company archetypes: global integrated gas producers (Linde, Air Liquide, Air Products) with vertically integrated ASU networks and global distribution infrastructure; regional specialists (Messer, SOL, Gulf Cryo, nexAir) with geographic concentration advantages in specific markets; and emerging niche players (Asia Industrial Gases, AMCS Corporation, Statebourne Cryogenics) focused on specialty applications. Three key trends identified by MRFR shape the market's structural direction: semiconductor fabrication expansion driving LN₂ demand at each new advanced-node fab consuming 15 to 30 tonnes of nitrogen products daily; biologics cold-chain mandates requiring cryogenic nitrogen for vaccine biobanking and cell therapy cryopreservation; and the Kigali Amendment HFC phase-down creating nitrogen-based refrigeration alternative demand. Three key opportunities define the highest-growth commercial vectors: cryogenic food processing in emerging economies where IQF freezing adoption in Southeast Asia and Africa represents a significant underpenetrated market; cell and gene therapy cryopreservation where CGT manufacturing expansion drives medical-grade LN₂ demand at 15 to 20% annual growth; and hydrogen economy synergies where liquid nitrogen infrastructure co-locates with green hydrogen production facilities for electrolyzer inerting and safety systems. The market listing identifies the following key companies: Linde, Asia Industrial Gases Pte. Ltd., Southern Industrial Gas Sdn Bhd, Air Liquide, nexAir LLC, Taiyo Nippon Sanso Corporation, Praxair Technology Inc., Air Products and Chemicals Inc., Gulf Cryo, AMCS Corporation, and Statebourne Cryogenics Ltd. Market Research Future assesses the Liquid Nitrogen Market expansion as structurally durable through 2035.
Why These Companies Are Leading the Market?
Market leadership in the global Liquid Nitrogen Market is determined by four structural competitive factors:
Fab-adjacent on-site ASU infrastructure creating decade-long semiconductor LN₂ revenue lock-in: Linde's TSMC Arizona on-site nitrogen supply, Air Liquide's EUR 200M SK hynix HBM fab investment, and TNSC's Kumamoto Kumamoto fab supply collectively demonstrate that semiconductor fab-adjacent on-site ASU contracts — 10 to 20-year supply agreements where the gas company builds, owns, and operates dedicated air separation units on or adjacent to fab premises — generate the most predictable and highest-value LN₂ revenue in the market, creating captive multi-decade supply relationships protected from spot-market competition.
Cell and gene therapy cryopreservation as the highest-growth new LN₂ application: Linde's and SOL's cell-therapy cryopreservation LN₂ supply programs, alongside TNSC's Japanese regenerative medicine manufacturing supply, demonstrate how the USD 45 billion global CGT manufacturing investment through 2030 is creating a new high-value medical LN₂ application segment — where GMP-validated cryogenic nitrogen supply for autologous and allogeneic CAR-T, stem cell, and gene therapy product manufacturing requires the most stringent purity and supply continuity specifications in any LN₂ application, enabling premium pricing for qualified medical-grade LN₂ producers.
Cryogenic food processing systems integration converting product to service revenue: The integration of Air Liquide's IQF tunnel freezer system and Air Products' cryogenic food process engineering capability shows how gas companies are shifting from the delivery of commodity LN₂ cylinders to the supply of cryogenic food process systems. In this scenario, the gas company designs, installs, and oversees the entire nitrogen freezing tunnel, charging per kilogram of frozen food rather than per liter of LN₂ delivered, creating recurring performance-based service revenue above commodity gas pricing.
Hydrogen economy synergies enabling co-investment LN₂ and LH₂ infrastructure positioning:Messer's sustainable gas strategy and Air Products' NEOM Green Hydrogen LN₂ infrastructure adjacency show how the emerging green hydrogen production economy—where electrolyzers need nitrogen for purging, inerting, and safety systems—creates co-investment opportunities that enable LN₂ producers to establish infrastructure positions at hydrogen hubs simultaneously serving the nitrogen and hydrogen gas markets from shared cryogenic facility investments.
SECTION 2 — TOP 10 GLOBAL LIQUID NITROGEN COMPANIES — MRFR RANKINGS (2026)
MRFR has identified and profiled the following leading liquid nitrogen companies globally as listed on the MRFR Liquid Nitrogen Market companies page: Linde, Asia Industrial Gases Pte. Ltd., Southern Industrial Gas Sdn Bhd, Air Liquide, nexAir LLC, Taiyo Nippon Sanso Corporation, Praxair Technology Inc., Air Products and Chemicals Inc., Gulf Cryo, AMCS Corporation, and Statebourne Cryogenics Ltd. These companies are evaluated on the basis of revenue performance, geographic presence, purity grade capability, application coverage, distribution infrastructure, and innovation track record.
|
# |
Company |
Headquarters |
Revenue (USD) |
Geographic Presence |
Key Specialization |
Notable Highlights |
|
1 |
Linde plc |
Guildford, UK / Dublin, Ireland |
~$33.0B (FY2024) |
100+ countries |
Leading global LN₂ producer; on-site ASU; medical-grade purity; AI purity-analytics; semiconductor fab-adjacent supply |
Medical-grade LN₂ for cell & gene therapy cryopreservation; fab-adjacent on-site LN₂ supply for TSMC Arizona; helium recycling JVs |
|
2 |
Air Liquide S.A. |
Paris, France |
~$28.6B (FY2024) |
80+ countries |
LN₂ cryogenic food processing; biologics cold-chain; hydrogen synergies; AI ASU purity control |
EUR 200M SK hynix HBM fab nitrogen investment (Jun 2026); DIG Airgas acquisition; advanced cryogenic food-tunnel freezing systems for emerging economies |
|
3 |
Air Products & Chemicals |
Allentown, PA, USA |
~$12.1B (FY2024) |
50+ countries |
On-site LN₂ generation; long-term take-or-pay model; green hydrogen synergies; NEOM project |
NEOM Green Hydrogen 80% construction (2025); electrolyzer-grade LN₂ inerting; ILA Best Practice Guide for cryogenic food freezing compliance |
|
4 |
Taiyo Nippon Sanso (TNSC) |
Tokyo, Japan |
~$8.9B (FY2024, total) |
Asia-Pacific, Americas, Europe (20+ countries) |
Medical-grade LN₂; semiconductor process gases; membrane separation; ASEAN fab expansion |
Semiconductor-grade LN₂ for TSMC Japan Kumamoto fab; ASEAN expansion for Malaysian and Vietnamese electronics fabs; cell therapy cryopreservation supply |
|
5 |
Messer Group |
Bad Soden, Germany |
~$4.8B (FY2024) |
40+ countries |
Portable LN₂ systems for remote locations; medical clinics; disaster relief; green CO₂ adjacency |
Portable LN₂ systems for mobile medical clinics and disaster relief (Aug 2023); green CO₂ plant Vrdy, Czech Republic (Dec 2024); EU CSRD sustainable gas supply |
|
6 |
SOL Group |
Milan, Italy |
~$1.5B (FY2024) |
20+ countries |
Medical LN₂; homecare cryotherapy; Southern European biopharma; cell therapy gas supply |
Medical and homecare LN₂ for Southern European biopharma and cell-therapy customers; expanding cryogenic food processing for Mediterranean food export markets (2025) |
|
7 |
nexAir LLC |
Memphis, TN, USA |
~$400M (FY2024, est.) |
Americas (US Southeast) |
Regional LN₂ distribution; food processing; metal fabrication; US Southeast market |
Expanding regional LN₂ distribution for US Southeast food processing, metal fabrication and industrial cryogenic applications; ILA cryogenic food compliance (2025) |
|
8 |
Gulf Cryo |
Dubai, UAE |
~$300M (FY2024, est.) |
Middle East, Africa (10+ countries) |
Industrial & medical LN₂; Gulf region leader; NEOM and Gulf hydrogen adjacency; petrochemical supply |
Gulf region industrial gas leader; supplying LN₂ for Saudi petrochemical and NEOM infrastructure; expanding medical-grade supply for Gulf biopharma (2025) |
|
9 |
Praxair Technology Inc. (Linde subsidiary) |
Danbury, CT, USA |
~$33.0B (FY2024, Linde total) |
Americas, Europe, Asia (30+ countries) |
Novel membrane-based N₂ separation (Oct 2023); LN₂ for food processing & industrial cryogenic |
Praxair introduces novel membrane-based nitrogen separation technology (Oct 2023) improving production efficiency; expanding US LN₂ food processing supply. |
|
10 |
Asia Industrial Gases Pte. Ltd |
Singapore |
~$200M (FY2024, est.) |
Asia-Pacific (Singapore, SE Asia) |
Industrial & electronic-grade LN₂; Singapore semiconductor and biomedical hub supply |
Singapore semiconductor and biomedical hub LN₂ specialist; expanding electronic-grade nitrogen for Malaysian and Singapore advanced manufacturing (2025) |
*Rankings based on MRFR analysis. Revenue figures sourced from official company filings and investor relations disclosures.
SECTION 3 — DETAILED COMPANY PROFILES
- Linde plc | NASDAQ: LIN | Guildford, UK / Dublin, Ireland
Company Overview: Linde plc is the world's largest liquid nitrogen producer, commanding a leading global market position through its vertically integrated air separation unit network that produces liquid nitrogen alongside liquid oxygen and liquid argon from atmospheric air cryogenic separation. Linde's LN₂ portfolio serves the complete application spectrum from commodity industrial cryogenic applications — metal fabrication, food blast freezing, and tire deflashing — through medical-grade LN₂ for cell and gene therapy cryopreservation and semiconductor-grade ultra-high-purity nitrogen for advanced fab processes requiring sub-ppb contamination levels.
2025–2026 Update: Linde is providing on-site LN₂ supply for TSMC's multi-phase gigafab build-out in Phoenix, Arizona — one of the largest semiconductor LN₂ supply contracts in US history — and advancing its cell and gene therapy cryopreservation supply chain through dedicated medical-grade LN₂ supply agreements with North American and European CGT manufacturers.
- Air Liquide S.A. | EPA: AI | Paris, France
Company Overview: Air Liquide S.A. is the world's second-largest liquid nitrogen producer, with operations spanning cryogenic food processing tunnels, biological sample cryopreservation, semiconductor fab nitrogen supply, and industrial metal-working cryogenic applications across 80+ countries. Air Liquide's cryogenic food processing systems — including individually quick-frozen tunnel freezers and plate freezers that use liquid nitrogen's -196°C temperature for rapid food freezing — serve the global food export industry's demand for high-quality blast-frozen seafood, meat, bakery, and ready-meal products.
2025–2026 Update: Air Liquide committed EUR 200 million in June 2026 to nitrogen supply for SK hynix's P&T7 HBM fab in Cheongju — one of the largest single-fab LN₂ supply investments in Korean semiconductor history. Air Liquide also completed the DIG Airgas acquisition to strengthen its North American distribution. Its cryogenic food processing systems are expanding into the cryogenic food processing in emerging economies opportunity — supplying IQF tunnel freezing systems to food processors in Southeast Asia and Sub-Saharan Africa, where cold-chain modernization is the primary food-loss reduction strategy
- Air Products & Chemicals | NYSE: APD | Allentown, PA, USA
Company Overview: Air Products & Chemicals is the world's third-largest liquid nitrogen producer, pioneering the on-site take-or-pay LN₂ supply model — building, owning, and operating dedicated ASUs on customer premises for 10- to 20-year contracted nitrogen supply — across semiconductor fab, food processing, and industrial cryogenic applications. Air Products' NEOM Green Hydrogen Project creates a strategic adjacency between liquid nitrogen and liquid hydrogen infrastructure, where nitrogen is used for electrolyzer stack inerting, purging, and safety systems at hydrogen production facilities.
2025–2026 Update: Air Products' NEOM Green Hydrogen Project reached 80% construction in 2025, targeting 650 tonnes per day of green hydrogen alongside nitrogen infrastructure for electrolysis operations — directly implementing the hydrogen economy synergies opportunity that MRFR identifies, where liquid nitrogen and liquid hydrogen infrastructure increasingly co-locate at renewable hydrogen production facilities. Air Products also joined the International Liquid Nitrogen Association's Best Practice Guide for cryogenic food freezing compliance.
- Taiyo Nippon Sanso Corporation (TNSC) | TYO: 4091 (Parent: Nippon Sanso Holdings) | Tokyo, Japan
Company Overview: Taiyo Nippon Sanso Corporation (TNSC) is Japan's leading liquid nitrogen producer, supplying semiconductor process-grade LN₂ to Japanese, Korean, and Taiwanese semiconductor fabs, medical-grade LN₂ for cryopreservation, and industrial LN₂ for food processing and metal fabrication across Asia-Pacific. TNSC's membrane separation technology — achieving ultra-high-purity nitrogen at 99.9999% via a molecular-sieve membrane rather than cryogenic separation — enables cost-efficient on-site LN₂-equivalent supply for mid-size semiconductor and pharmaceutical facilities.
2025–2026 Update: TNSC expanded semiconductor-grade LN₂ supply for TSMC's new Japan Kumamoto fab in 2025, alongside advancing ASEAN expansion for Malaysian and Vietnamese electronics fab LN₂ customers as semiconductor manufacturing diversifies from Taiwan. TNSC's cell therapy cryopreservation supply capabilities are also expanding for Japan's growing regenerative medicine manufacturing sector.
- Messer Group | Private | Bad Soden, Germany
Company Overview: Messer Group is Europe's largest privately owned industrial gas company with a significant liquid nitrogen business serving medical, food processing, and industrial applications across Central and Eastern Europe, the US, and Latin America. Messer's portable liquid nitrogen systems — including mobile dewars and transportable cryogenic containers for remote medical clinics and disaster relief operations — represent a distinctive product niche enabling LN₂ supply to locations without fixed pipeline or bulk delivery infrastructure.
2025–2026 Update: Messer unveiled its new line of portable liquid nitrogen systems for remote locations in August 2023, targeting mobile medical clinics and disaster relief operations where conventional bulk LN₂ delivery is logistically unavailable. Messer also commissioned a renewable CO₂ plant in Vrdy, Czech Republic, in December 2024 as part of its sustainable industrial gas strategy. Market Research Future identifies Messer's portable LN₂ system innovation as uniquely aligned with emergency preparedness and remote healthcare applications, expanding the Liquid Nitrogen Market into locations previously unserved by conventional supply chains.
- SOL Group | BIT: SOL | Milan, Italy
Company Overview: SOL Group is a Southern European specialty industrial gas company with a growing liquid nitrogen business serving medical cryotherapy, homecare oxygen and cryogenic applications, and specialty biopharma manufacturing customers across Italy, Greece, Spain, and broader Mediterranean markets. SOL's medical LN₂ portfolio — supplying dermatology clinics with cryotherapy nitrogen, fertility clinics with gamete cryopreservation LN₂, and biomanufacturers with GMP-grade cryogenic gas — serves the highest-value medical application segments of the Liquid Nitrogen Market.
2025–2026 Update: In 2025, SOL Group increased its medical and homecare LN₂ supply for Southern European biopharma and cell-therapy clients, focusing on the cryopreservation possibility for cell and gene therapy as Spain's and Italy's CGT manufacturing industries expand due to EU Advanced Therapy Medicinal Product regulatory approvals. Additionally, SOL is increasing the supply of cryogenic food processing for food exporters in the Mediterranean region.
- nexAir LLC | Private | Memphis, TN, USA
Company Overview: nexAir LLC is a regional US liquid nitrogen distributor serving the US Southeast market — including Tennessee, Georgia, Alabama, Mississippi, and adjacent states — with bulk and cylinder LN₂ supply for food processing, metal fabrication, automotive parts deflashing, and industrial cryogenic applications. nexAir's regional distribution model — with its own fleet of cryogenic transport vehicles and strategically located LN₂ storage depots — enables just-in-time delivery service to US Southeast industrial customers that national suppliers cannot match with equivalent regional responsiveness.
2025–2026 Update: nexAir expanded regional LN₂ distribution in 2025 for US Southeast food processing, metal fabrication, and industrial cryogenic applications, positioning itself to serve the growing US Southeast automotive and food manufacturing investment corridor.
- Gulf Cryo | Private | Dubai, UAE
Company Overview: Gulf Cryo is the leading industrial gas company in the Gulf Cooperation Council region, producing and distributing liquid nitrogen, liquid oxygen, and industrial gases for the Middle East's petrochemical, healthcare, and food industries from its production facilities in the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman. Gulf Cryo's regional network — spanning all six GCC states — enables consistent LN₂ supply to the Gulf's massive petrochemical processing, medical, and construction sectors.
2025–2026 Update: Gulf Cryo expanded LN₂ supply in 2025 for Saudi petrochemical and NEOM infrastructure projects, alongside growing medical-grade nitrogen for Gulf biopharma manufacturing expansion under Saudi Vision 2030's healthcare localization program.
- Praxair Technology Inc. (Linde subsidiary) | NASDAQ: LIN (Parent) | Danbury, CT, USA
Company Overview: Praxair Technology Inc., now fully integrated within Linde following the 2018 merger, operates as Linde's North American LN₂ and industrial gas production and distribution arm — encompassing the former Praxair brand's extensive US ASU network, cryogenic transport fleet, and long-standing industrial customer supply relationships in food processing, metal fabrication, and electronics manufacturing. The Praxair brand legacy continues in North American industrial supply relationships while operating within Linde's global strategy.
2025–2026 Update: Praxair (Linde) introduced a novel membrane-based nitrogen separation technology in October 2023, aimed at optimizing production efficiency and lowering costs for on-site nitrogen generation at mid-size industrial facilities — directly addressing the hydrogen economy synergies and on-site generation efficiency opportunity.
- Asia Industrial Gases Pte. Ltd | Private | Singapore
Company Overview: Asia Industrial Gases Pte. Ltd. is a specialist industrial gas firm established in Singapore that supplies electronic-grade gases, liquid nitrogen, and liquid oxygen to Southeast Asian industrial markets as well as Singapore's semiconductor and biomedical manufacturing sector. With its headquarters in Singapore, Asia Industrial Gases is situated in the heart of ASEAN's innovative industrial sector, catering to semiconductor factories, pharmaceutical companies, and biomedical research facilities that need reliable supplies of medical-grade and electronic-grade LN₂.
2025–2026 Update: In 2025, Asia Industrial Gases increased its supply of electronic-grade nitrogen to Malaysian and Singaporean advanced manufacturing clients, focusing on the rapidly expanding semiconductor and biomedical manufacturing sectors in ASEAN as international chip and pharmaceutical companies shift their production from Taiwan and China to ASEAN.